Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc.

77 employees · est. 2018 · United States

VS
Solid IO logo

Solid IO

ENDING THE GUESSWORK IN CANCER CARE | Patient-specific organ-on-chip technology for precision oncology & immunotherapy

8 employees · est. 2025 · Helsinki, Finland

Acrivon Therapeutics, Inc. is the older company (2018 vs 2025); Acrivon Therapeutics, Inc. is the larger of the two.

Side-by-Side Comparison

Acrivon Therapeutics, Inc. Solid IO
Founded
2018 older 2025
Headquarters
United States Helsinki, Finland
Employees
77 larger 8
Industry
Biotechnology, Health Care, Health and Wellness Not tracked yet
Funding Stage
Post Ipo Equity Seed
Total Funding
$245.50M $800.00K
Funding Rounds
3 1
Services
Not tracked yet Tumor-on-chip platform, Patient-specific treatment insights, Immunotherapy research support, Early-stage clinical trial facilitation
Target Customers
Not tracked yet Pharmaceutical Companies, Biotech Firms, Cancer Clinics, Oncologists, Researchers
Taxonomy
Precision Oncology, Therapeutics, Proteomics, Patient Selection, Oncology Drug Targets, Clinical-stage Assets, Pipeline Development, Biomarker Discovery, Clinical Trials, Cancer Treatment, Drug Development, Boston Area, Lund, Sweden, Innovation Organ-on-chip Technology, Precision Oncology, Immunotherapy, Tumor Microenvironment, Clinical Trials Optimization, Drug Development Acceleration, Biomarker Validation, Personalized Immunotherapies, Cancer Research, Patient-specific Treatment, Oncology Data Insights, Pharmaceutical Innovation, Biotech Collaboration, Precision Medicine
Website
acrivon.com solid-io.com
Acrivon Therapeutics, Inc. logo

About Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc. is a precision oncology therapeutics company with a unique proteomics-based patient selection platform. The company is focused on challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single gene driver mut...

Solid IO logo

About Solid IO

Solid IO, founded in 2025 and headquartered in Finland, is pioneering advancements in precision oncology and immunotherapy through its unique organ-on-chip technology. The company's slogan, "ENDING THE GUESSWORK IN CANCER CARE," underscores its commitment to providing patient-specific data that empo...

We will tell you when either one moves

BounceWatch watches Acrivon Therapeutics, Inc. and Solid IO for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Acrivon Therapeutics,... and Solid IO — by email.

Frequently Asked Questions

Acrivon Therapeutics, Inc.. Solid IO — ENDING THE GUESSWORK IN CANCER CARE | Patient-specific organ-on-chip technology for precision oncology & immunotherapy. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Acrivon Therapeutics, Inc. has raised $245.50M while Solid IO has raised $800.00K.
Acrivon Therapeutics, Inc. and Solid IO operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Acrivon Therapeutics, Inc. with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Acrivon Therapeutics, Inc. on 12 Sep 2024, and Solid IO on 13 Nov 2025. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy